Human Immunodeficiency Virus (HIV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Human immunodeficiency virus (HIV), a lentivirus in the retrovirus family, exhibits remarkable heterogeneity due to high viral load, rapid turnover rates, an error-prone reverse transcriptase enzyme, and viral genome recombination within infected individuals. Retroviruses, characterized by extended incubation periods, like HIV, gradually lead to clinical latency and eventual onset of AIDS symptoms, inflicting severe damage on the immune system by exploiting CD4+ cells for replication, ultimately destroying these cells. Zoonotic transmissions from nonhuman primates to humans have spawned diverse HIV lineages: HIV-1 groups M, N, O, and P and HIV-2 groups A-H. HIV-1 group M, responsible for the global pandemic, shares a direct but independent origin from SIVcpz in chimpanzees. For treating HIV infection, the FDA has approved over two dozen antiretroviral drugs, which can be categorized into six groups: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Fusion Inhibitors, Capsid Inhibitor, gp120 Attachment Inhibitor, and CCR5 Antagonist.

·       In 2022, an estimated 1.3 million individuals worldwide acquired HIV, with women and girls accounting for 46% of new infections.

Thelansis’s “Human Immunodeficiency Virus (HIV) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Human Immunodeficiency Virus (HIV) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Human Immunodeficiency Virus (HIV) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Human Immunodeficiency Virus (HIV) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Human Immunodeficiency Virus (HIV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Human Immunodeficiency Virus (HIV), Human Immunodeficiency Virus (HIV) market outlook, Human Immunodeficiency Virus (HIV) competitive landscape, Human Immunodeficiency Virus (HIV) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)